Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

{ 'indexed': {'date-parts': [[2024, 5, 14]], 'date-time': '2024-05-14T09:07:00Z', 'timestamp': 1715677620564}, 'reference-count': 29, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 9, 28]], 'date-time': '2020-09-28T00:00:00Z', 'timestamp': 1601251200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'name': 'Chinese COVID-19 scientific research emergency project', 'award': ['2020YFC0844100', '2020YFC0846800']}, { 'name': 'China Mega-Project for Infectious Diseases', 'award': ['2017ZX10203202', '2013ZX10002005']}, {'name': 'China Mega-Project for Innovative Drugs', 'award': ['2016ZX09101065']}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'em-consulte.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 1]]}, 'DOI': '10.1016/j.biopha.2020.110825', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 30]], 'date-time': '2020-09-30T01:24:58Z', 'timestamp': 1601429098000}, 'page': '110825', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 74, 'title': 'Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a ' 'small sample size', 'prefix': '10.1016', 'volume': '133', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-8069-9901', 'authenticated-orcid': False, 'given': 'Hong', 'family': 'Zhao', 'sequence': 'first', 'affiliation': []}, {'given': 'Qi', 'family': 'Zhu', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5989-0736', 'authenticated-orcid': False, 'given': 'Chi', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jiawen', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ming', 'family': 'Wei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yuhong', 'family': 'Qin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guilin', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ke', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Junhua', 'family': 'Yu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhao', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xianxiang', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guiqiang', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '13', 'key': '10.1016/j.biopha.2020.110825_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '1199', 'DOI': '10.1056/NEJMoa2001316', 'article-title': 'Early transmission dynamics in Wuhan, China, of novel ' 'coronavirus-infected pneumonia', 'volume': '382', 'author': 'Li', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0010', 'unstructured': 'http://2019ncov.chinacdc.cn/2019-nCoV/global.html (Accessed 28 May ' '2020).'}, { 'issue': '13', 'key': '10.1016/j.biopha.2020.110825_bib0015', 'doi-asserted-by': 'crossref', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and important lessons from the coronavirus disease ' '2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases ' 'from the chinese center for disease control and prevention', 'volume': '323', 'author': 'Wu', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '5', 'key': '10.1016/j.biopha.2020.110825_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '105954', 'DOI': '10.1016/j.ijantimicag.2020.105954', 'article-title': 'Cytokine release syndrome in severe COVID-19: interleukin-6 receptor ' 'antagonist tocilizumab may be the key to reduce mortality', 'volume': '55', 'author': 'Zhang', 'year': '2020', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.biopha.2020.110825_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '104946', 'DOI': '10.1016/j.phrs.2020.104946', 'article-title': 'Biochemical indicators of coronavirus disease 2019 exacerbation and the ' 'clinical implications', 'author': 'An', 'year': '2020', 'journal-title': 'Pharmacol. Res.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0030', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.cytogfr.2020.05.003', 'article-title': 'The cytokine storm in COVID-19: an overview of the involvement of the ' 'chemokine/chemokine-receptor system', 'author': 'Coperchini', 'year': '2020', 'journal-title': 'Cytokine Growth Factor Rev.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0035', 'article-title': 'Level of IL-6 predicts respiratory failure in hospitalized symptomatic ' 'COVID-19 patients', 'author': 'Herold', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.biopha.2020.110825_bib0040', 'article-title': 'The role of interleukin-6 in monitoring severe case of coronavirus ' 'disease 2019', 'author': 'Liu', 'year': '2020', 'journal-title': 'EMBO Mol. Med.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0045', 'unstructured': 'Instruction of Tocilizumab ' 'https://www.gene.com/download/pdf/actemra_prescribing.pdf (Accessed 28 ' 'May 2020).'}, { 'issue': '7', 'key': '10.1016/j.biopha.2020.110825_bib0050', 'doi-asserted-by': 'crossref', 'first-page': '2217', 'DOI': '10.1182/blood.V94.7.2217.419k02_2217_2224', 'article-title': 'Cytokine-release syndrome in patients with B-cell chronic lymphocytic ' 'leukemia and high lymphocyte counts after treatment with an anti-CD20 ' 'monoclonal antibody (rituximab, IDEC-C2B8)', 'volume': '94', 'author': 'Winkler', 'year': '1999', 'journal-title': 'Blood'}, { 'issue': '16', 'key': '10.1016/j.biopha.2020.110825_bib0055', 'doi-asserted-by': 'crossref', 'first-page': '1509', 'DOI': '10.1056/NEJMoa1215134', 'article-title': 'Chimeric antigen receptor-modified T cells for acute lymphoid leukemia', 'volume': '368', 'author': 'Grupp', 'year': '2013', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0060', 'article-title': 'Pathogenic T-cells and inflammatory monocytes incite inflammatory ' 'storms in severe COVID-19 patients', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Sci. Rev.'}, { 'issue': '20', 'key': '10.1016/j.biopha.2020.110825_bib0065', 'doi-asserted-by': 'crossref', 'first-page': '10970', 'DOI': '10.1073/pnas.2005615117', 'article-title': 'Effective treatment of severe COVID-19 patients with tocilizumab', 'volume': '117', 'author': 'Xu', 'year': '2020', 'journal-title': 'Proc. Natl. Acad. Sci.'}, { 'issue': '2', 'key': '10.1016/j.biopha.2020.110825_bib0070', 'doi-asserted-by': 'crossref', 'first-page': '446', 'DOI': '10.1016/j.antiviral.2013.09.015', 'article-title': 'Favipiravir (T-705), a novel viral RNA polymerase inhibitor', 'volume': '100', 'author': 'Furuta', 'year': '2013', 'journal-title': 'Antiviral Res.'}, { 'issue': '3', 'key': '10.1016/j.biopha.2020.110825_bib0075', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0080', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eng.2020.03.007', 'article-title': 'Experimental treatment with Favipiravir for COVID-19: an open-label ' 'control study', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering'}, { 'key': '10.1016/j.biopha.2020.110825_bib0085', 'series-title': 'Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia', 'year': '2020'}, { 'issue': '12', 'key': '10.1016/j.biopha.2020.110825_bib0090', 'doi-asserted-by': 'crossref', 'first-page': '773', 'DOI': '10.1038/s41577-018-0066-7', 'article-title': 'Recent insights into targeting the IL-6 cytokine family in inflammatory ' 'diseases and cancer', 'volume': '18', 'author': 'Jones', 'year': '2018', 'journal-title': 'Nat. Rev. Immunol.'}, { 'issue': '5', 'key': '10.1016/j.biopha.2020.110825_bib0095', 'doi-asserted-by': 'crossref', 'first-page': '448', 'DOI': '10.1038/ni.3153', 'article-title': 'IL-6 as a keystone cytokine in health and disease', 'volume': '16', 'author': 'Hunter', 'year': '2015', 'journal-title': 'Nat. Immunol.'}, { 'issue': '2', 'key': '10.1016/j.biopha.2020.110825_bib0100', 'doi-asserted-by': 'crossref', 'first-page': '83', 'DOI': '10.1016/j.cytogfr.2011.02.003', 'article-title': 'IL-6 signaling in autoimmunity, chronic inflammation and ' 'inflammation-associated cancer', 'volume': '22', 'author': 'Neurath', 'year': '2011', 'journal-title': 'Cytokine Growth Factor Rev.'}, { 'issue': '11', 'key': '10.1016/j.biopha.2020.110825_bib0105', 'doi-asserted-by': 'crossref', 'first-page': '1516', 'DOI': '10.1136/ard.2008.092932', 'article-title': 'IL-6 receptor inhibition with tocilizumab improves treatment outcomes ' 'in patients with rheumatoid arthritis refractory to anti-tumour ' 'necrosis factor biologicals: results from a 24-week multicentre ' 'randomised placebo-controlled trial', 'volume': '67', 'author': 'Emery', 'year': '2008', 'journal-title': 'Ann. Rheum. Dis.'}, { 'issue': '10', 'key': '10.1016/j.biopha.2020.110825_bib0110', 'doi-asserted-by': 'crossref', 'first-page': '2968', 'DOI': '10.1002/art.23940', 'volume': '58', 'author': 'Genovese', 'year': '2008', 'journal-title': 'Arthritis Rheum.'}, { 'issue': '2', 'key': '10.1016/j.biopha.2020.110825_bib0115', 'doi-asserted-by': 'crossref', 'first-page': '189', 'DOI': '10.1586/eci.10.2', 'article-title': 'The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis', 'volume': '6', 'author': 'Jones', 'year': '2010', 'journal-title': 'Expert Rev. Clin. Immunol.'}, { 'issue': '9617', 'key': '10.1016/j.biopha.2020.110825_bib0120', 'doi-asserted-by': 'crossref', 'first-page': '987', 'DOI': '10.1016/S0140-6736(08)60453-5', 'article-title': 'Effect of interleukin-6 receptor inhibition with tocilizumab in ' 'patients with rheumatoid arthritis (OPTION study): a double-blind, ' 'placebo-controlled, randomised trial', 'volume': '371', 'author': 'Smolen', 'year': '2008', 'journal-title': 'Lancet'}, { 'issue': '10', 'key': '10.1016/j.biopha.2020.110825_bib0125', 'doi-asserted-by': 'crossref', 'first-page': '3959', 'DOI': '10.1182/blood-2008-05-155846', 'article-title': 'Mechanisms and pathologic significances in increase in serum ' 'interleukin-6 (IL-6) and soluble IL-6 receptor after administration of ' 'an anti–IL-6 receptor antibody, tocilizumab, in patients with ' 'rheumatoid arthritis and Castleman disease', 'volume': '112', 'author': 'Nishimoto', 'year': '2008', 'journal-title': 'Blood'}, { 'issue': '5', 'key': '10.1016/j.biopha.2020.110825_bib0130', 'doi-asserted-by': 'crossref', 'first-page': '610', 'DOI': '10.1007/s11684-019-0714-8', 'article-title': 'Management of cytokine release syndrome related to CAR-T cell therapy', 'volume': '13', 'author': 'Chen', 'year': '2019', 'journal-title': 'Front. Med.'}, { 'issue': '9', 'key': '10.1016/j.biopha.2020.110825_bib0135', 'doi-asserted-by': 'crossref', 'first-page': '1143', 'DOI': '10.1136/annrheumdis-2020-218479', 'article-title': 'Historically controlled comparison of glucocorticoids with or without ' 'tocilizumab versus supportive care only in patients with ' 'COVID-19-associated cytokine storm syndrome: results of the CHIC study', 'volume': '79', 'author': 'Ramiro', 'year': '2020', 'journal-title': 'Ann. Rheum. Dis.'}, { 'key': '10.1016/j.biopha.2020.110825_bib0140', 'article-title': 'Tocilizumab for treatment of mechanically ventilated patients with ' 'COVID-19', 'author': 'Somers', 'year': '2020', 'journal-title': 'Clin. Infect. Dis.'}, { 'issue': '10', 'key': '10.1016/j.biopha.2020.110825_bib0145', 'doi-asserted-by': 'crossref', 'first-page': '1277', 'DOI': '10.1136/annrheumdis-2020-218122', 'article-title': 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with ' 'systemic hyperinflammation: an open-label cohort study', 'volume': '79', 'author': 'Della-Torre', 'year': '2020', 'journal-title': 'Ann. Rheum. Dis.'}], 'container-title': 'Biomedicine & Pharmacotherapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0753332220310180?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0753332220310180?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2024, 1, 22]], 'date-time': '2024-01-22T17:31:08Z', 'timestamp': 1705944668000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0753332220310180'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1]]}, 'references-count': 29, 'alternative-id': ['S0753332220310180'], 'URL': 'http://dx.doi.org/10.1016/j.biopha.2020.110825', 'relation': {}, 'ISSN': ['0753-3322'], 'subject': [], 'container-title-short': 'Biomedicine & Pharmacotherapy', 'published': {'date-parts': [[2021, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Tocilizumab combined with favipiravir in the treatment of COVID-19: A ' 'multicenter trial in a small sample size', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Biomedicine & Pharmacotherapy', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.biopha.2020.110825', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Published by Elsevier Masson SAS.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '110825'}